Vemurafenib significantly decreases glomerular filtration rate

Journal of the European Academy of Dermatology and Venereology

Volumn 28, Issue 7, 2014, Pages 978-979

  Uthurriague, C ^a   Thellier, S ^a   Ribes, D ^a   Rostaing, L ^a   Paul, C ^a   Meyer, N ^a,b  

^a UNIVERSITÉ PAUL SABATIER   (France)

^b INSTITUT CLAUDIUS REGAUD   (France)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN TYROSINE KINASE INHIBITOR; VEMURAFENIB; INDOLE DERIVATIVE; PROTEIN KINASE INHIBITOR; SULFONAMIDE;

DISEASE SEVERITY; GLOMERULUS FILTRATION RATE; HAND FOOT SYNDROME; HUMAN; LETTER; METASTATIC MELANOMA; NEPHROTOXICITY; PRIORITY JOURNAL; QT PROLONGATION; SIDE EFFECT; ADULT; AGED; ALBUMINURIA; CANCER STAGING; DRUG EFFECTS; FEMALE; INCIDENCE; KIDNEY; MALE; MELANOMA; MIDDLE AGED; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; PROTEINURIA; RETROSPECTIVE STUDY; SKIN NEOPLASMS;

ADULT; AGED; ALBUMINURIA; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; INCIDENCE; INDOLES; KIDNEY; MALE; MELANOMA; MIDDLE AGED; NEOPLASM STAGING; PROTEIN KINASE INHIBITORS; PROTEINURIA; RETROSPECTIVE STUDIES; SKIN NEOPLASMS; SULFONAMIDES;

EID: 84904999097     PISSN: 09269959     EISSN: 14683083     Source Type: Journal    
DOI: 10.1111/jdv.12322     Document Type: Letter

References (5)

1. Drugs@FDA: FDA Approved Drug Products [Internet]. [citated 18 sep 2013]. available on: http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm? fuseaction=Search.Label-ApprovalHistory#apphist
2. Chapman PB, Hauschild A, Robert C, et al,. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011; 364: 2507-2516.
3. Balch CM, Gershenwald JE, Soong S-J, et al,. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 2009; 27: 6199-6206.
4. Jhaveri KD, Flombaum CD, Kroog G, Glezerman IG,. Nephrotoxicities associated with the use of tyrosine kinase inhibitors: a single-center experience and review of the literature. Nephron Clin Pract 2011; 117: c312-c319.
5. Halimi J-M, Azizi M, Bobrie G, et al,. Vascular and renal effects of anti-angiogenic therapy. Nephrol Ther 2008; 4: 602-615.